S218: A PHASE I/II STUDY OF GOLIDOCITINIB, A SELECTIVE JAK1 INHIBITOR, IN REFRACTORY OR RELAPSED PERIPHERAL T CELL LYMPHOMA

• W.-S. Kim,
• D.-H. Yoon,
• Y. Song,
• H. Yang,
• J. Cao,
• D. Ji,
• Y. Koh,
• H. Jing,
• H.-S. Eom,
• J.-Y. Kwak,
• W.-S. Lee,
• J.-S. Lee,
• H.-J. Shin,
• J. Jin,
• M. Wang,
• J. Li,
• X. Huang,
• X. Deng,
• Z. Yang,
• J. Zhu

Affiliations

W.-S. Kim

1 Department of Hematology and Oncology, Samsung Medical Center

D.-H. Yoon

2 Department of Oncology - Hematologic Cancer & BMT center, Asan Medical Center, Seoul, South Korea

Y. Song

3 Department of Lymphoma, Peking University Cancer Hospital, Beijing

H. Yang

4 Department of Lymphoma, Zhejiang Cancer Hospital, Hangzhou

J. Cao

5 Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

D. Ji

5 Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

Y. Koh

6 Department of Hemato-Oncology Center, Seoul National University Hospital, Seoul, South Korea

H. Jing

7 Department of Hematology, Peking University Third Hospital, Beijing, China

H.-S. Eom

8 Center for Hematologic Malignancy, National Cancer Center, Goyang

J.-Y. Kwak

9 Department of Hemato-Oncology Center, Chonbuk National University Hospital, Jeonju

W.-S. Lee

10 Department of Hemato-Oncology Center, Inje University Busan Paik Hospital, Busan

J.-S. Lee

11 Department of Hematology & Medical Oncology, Seoul National University Bundang Hospital, Seongnam

H.-J. Shin

12 Department of Hemato-Oncology Center, Pusan National University Hospital, Busan, South Korea

J. Jin

13 Department of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou

M. Wang

14 Clinical Development, Dizal Pharmaceutical, Shanghai, China

J. Li

14 Clinical Development, Dizal Pharmaceutical, Shanghai, China

X. Huang

14 Clinical Development, Dizal Pharmaceutical, Shanghai, China

X. Deng

14 Clinical Development, Dizal Pharmaceutical, Shanghai, China

Z. Yang

14 Clinical Development, Dizal Pharmaceutical, Shanghai, China

J. Zhu

3 Department of Lymphoma, Peking University Cancer Hospital, Beijing